Private DMEK corneal transplant cost UK 2026

What is Descemet membrane endothelial keratoplasty (DMEK)?

Descemet membrane endothelial keratoplasty (DMEK) is a partial-thickness corneal transplant developed and first reported by Gerrit Melles and the Netherlands Institute for Innovative Ocular Surgery (NIIOS) in 2006. DMEK replaces only the diseased posterior layers of the cornea — the Descemet membrane and the corneal endothelium — with a healthy donor Descemet-endothelium complex, leaving the patient's own anterior stroma and epithelium intact.

The donor graft is an extraordinarily thin tissue layer, typically 10 to 15 micrometres thick, prepared from a donor cornea by careful peeling of the Descemet membrane and its attached single layer of endothelial cells. It is loaded into a graft injector, introduced into the patient's anterior chamber through a 2.4 to 2.8 mm clear corneal incision, unfolded under air or balanced salt solution, and apposed to the patient's posterior stroma. A 20 per cent sulphur hexafluoride (SF6) gas or air bubble is then left in the anterior chamber to hold the graft against the host stroma until natural endothelial pumping and adhesion takes over (typically 6 to 24 hours).

Compared with the previous standard, Descemet stripping automated endothelial keratoplasty (DSAEK, which transplants a thicker ~100 to 150 micron lenticule that includes Descemet, endothelium and a slim layer of posterior stroma), DMEK gives faster visual recovery, better final best-corrected visual acuity (BCVA), less hyperopic shift (~+0.25 D versus +1.25 D for DSAEK) and a significantly lower rejection rate. Compared with full-thickness penetrating keratoplasty (PK), DMEK gives much better preserved corneal biomechanics, a near-neutral refraction, an order-of-magnitude lower rejection rate, and a much faster return to function. The procedure is 30 to 60 minutes per eye, day-case, topical or sub-Tenon's anaesthetic.

UK 2026 DMEK pricing, in detail

UK 2026 DMEK pricing varies with whether the procedure is DMEK alone or combined with cataract surgery ("Triple DMEK"), the NHSBT donor tissue fee (a substantial pass-through cost, ~£900 to £1,400 per graft), the centre overhead and the seniority of the corneal subspecialty consultant. The fee should be quoted as an all-inclusive package covering the corneal assessment, anterior segment imaging, donor tissue, the day-case procedure, intra-operative gas tamponade, and the full schedule of postoperative reviews including any necessary re-bubbling in the first 2 weeks.

For related corneal pricing see our private corneal transplant price guide, our DSAEK guide and our DMEK vs DSAEK vs PK overview.

What should be included in a private DMEK package in the UK in 2026?

• Corneal subspecialty consultant — a UK GMC specialist registered consultant ophthalmologist with documented corneal fellowship, doing at least 30 to 50 DMEK procedures a year, with audit data (re-bubbling rate, primary graft failure rate, 1-year endothelial cell density, 1-year BCVA) available on request.
• Full preoperative work-up — slit-lamp, dilated examination, anterior segment OCT (to confirm Descemet thickening, guttae, stromal oedema, the extent of central oedema and any anterior chamber pathology), Pentacam HR Scheimpflug tomography (pachymetry, anterior elevation, posterior elevation), specular microscopy endothelial cell count where the cornea is clear enough to image, OCT macula (to exclude macular pathology that would limit visual benefit), and IOP measurement.
• NHSBT donor tissue — the donor cornea is sourced via NHS Blood and Transplant (NHSBT) under the UK Transplant Registry, donor-quality-assessed with endothelial cell count and serology, prepared by an NHSBT-accredited eye bank technician or by the surgeon at the time of surgery; the donor tissue fee is a pass-through line-item (~£900 to £1,400) and should be itemised in the quote.
• Indication confirmation — Fuchs endothelial dystrophy with corneal oedema or symptomatic guttae, pseudophakic / aphakic bullous keratopathy, failed previous DMEK / DSAEK / PK with endothelial dysfunction, posterior polymorphous corneal dystrophy with endothelial failure, iridocorneal endothelial (ICE) syndrome with corneal decompensation, congenital hereditary endothelial dystrophy (CHED), or other isolated endothelial disease.
• Combined Triple DMEK if cataract — if there is a visually significant cataract or near-significant cataract in a Fuchs dystrophy eye, the standard 2026 pathway is combined DMEK plus phacoemulsification plus IOL implantation in the same operation, which avoids a second operation and the cumulative endothelial cell loss of staged surgery.
• Day-case DMEK under topical or sub-Tenon's anaesthetic — 2.4 to 2.8 mm main incision, 2 to 3 paracentesis ports, peripheral inferior surgical iridotomy at 6 o'clock (to avoid pupil block from the gas bubble), Descemet stripping under air, injection of the pre-loaded DMEK graft, unfolding using tapping / Yoeruek manoeuvres, apposition to the host stroma, intra-operative air or 20 per cent SF6 gas tamponade for 6 to 24 hours.
• Postoperative regime — supine posturing for 24 to 48 hours, topical steroid (intensive initial then long taper for 12 months or longer), topical antibiotic for 1 to 2 weeks, IOP-lowering cover if pre-existing glaucoma.
• Structured 1-day, 1-week, 1-month, 3-month and 12-month reviews with anterior segment OCT to confirm graft attachment.
• Re-bubbling guarantee — if graft detachment greater than one-third is detected on anterior segment OCT in the first 2 weeks, re-bubbling (in-clinic air injection) is included at no additional charge.
• CQC-registered theatre with the latest report rated Good or Outstanding, transparent itemised written pricing (with the NHSBT donor tissue fee listed separately), and direct telephone access to the consultant for 90 days postoperatively.
• Honest expectation-setting — about the 10 to 25 per cent early re-bubbling rate, the 1 to 5 per cent primary graft failure rate, the 1 to 2 per cent annual rejection risk requiring topical steroid for life, the lifelong endothelial cell density attrition (~7 to 10 per cent per year), and the realistic prospect of a repeat DMEK at 10 to 20 years.

What does the evidence say about DMEK?

DMEK is one of the most rigorously evidence-supported corneal interventions and the evidence base is consistent across the major datasets:

• Foundational DMEK papers (Melles et al., Cornea 2006; Br J Ophthalmol 2008) — first description of selective transplantation of the Descemet membrane and endothelium, with rapid visual recovery and very low rejection compared with DSAEK and PK.
• Price et al. (Ophthalmology 2014, 2016, 2018) — large prospective DMEK series from Indianapolis showing BCVA 6/9 or better in ~80 to 90 per cent of eyes at 6 months, hyperopic shift of ~+0.25 D (much less than DSAEK), and rejection rate of ~1 per cent at 1 year and ~3 per cent at 4 years on topical steroid.
• NICE IPG 632 Descemet membrane endothelial keratoplasty (2019) — NICE concluded that the evidence on DMEK shows efficacy in improving visual acuity in patients with endothelial dysfunction and that the safety profile is comparable with other endothelial keratoplasty techniques. Standard NICE arrangements for clinical governance, consent and audit apply.
• NHSBT UK Transplant Registry / Ocular Tissue Advisory Group (OTAG) — UK-wide data on corneal transplant outcomes including endothelial keratoplasty, showing DMEK adoption rising year on year as the predominant technique for endothelial disease in the UK NHS and private sector.
• EuCornea / ESCRS Cornea Day Working Group statements — DMEK positioned as the standard of care for isolated endothelial disease where technically feasible; DSAEK reserved for cases where DMEK is technically unsafe (shallow anterior chamber, aniridia, glaucoma drainage device, vitrectomised eyes).
• Cochrane Review of endothelial keratoplasty (most recent update) — DMEK shows faster visual recovery and better final BCVA than DSAEK; rejection rate is significantly lower; overall complication rate is comparable. DMEK has a slightly higher re-bubbling rate (10 to 25 per cent vs ~3 to 5 per cent for DSAEK) but does not result in a higher primary graft failure rate in experienced hands.
• AAO Cornea Preferred Practice Pattern — DMEK supported as the technique of choice for isolated endothelial dysfunction in eyes where technically feasible.
• Cost-effectiveness — DMEK is cost-saving versus repeated drops, repeated DSAEK, repeated PK and the productivity loss of prolonged visual recovery from a thicker graft in working-age patients.

In short: DMEK is the modern gold standard endothelial keratoplasty, with fast visual recovery, near-neutral refraction, low rejection, an order-of-magnitude lower rejection rate than full-thickness penetrating keratoplasty, and a re-bubbling rate that is manageable in clinic.

DMEK vs DSAEK vs PK: which is right for me?

Each corneal transplant technique has a defined modern indication:

• DMEK — the modern gold standard for isolated endothelial disease (Fuchs endothelial dystrophy, pseudophakic bullous keratopathy, failed previous endothelial graft). 10 to 15 micron Descemet-endothelium graft. Fastest visual recovery, best final BCVA, near-neutral refraction (~+0.25 D hyperopic shift), lowest rejection rate (1 to 2 per cent). Technically demanding; not always feasible in shallow anterior chambers, aniridia, large iris defects, vitrectomised eyes or eyes with glaucoma drainage devices.
• DSAEK — the previous standard for isolated endothelial disease. 100 to 150 micron Descemet-stroma-endothelium lenticule. Slightly slower visual recovery, slightly lower final BCVA (often 6/9 to 6/12), small hyperopic shift (~+1.25 D), low rejection rate (~5 to 10 per cent). Indicated where DMEK is technically not feasible. Slightly lower re-bubbling rate than DMEK.
• Penetrating keratoplasty (PK) — full-thickness corneal transplant. Reserved for combined stromal and endothelial disease (e.g. herpetic stromal scar with endothelial failure, post-traumatic full-thickness scar), perforation repair, or selected re-grafts. Slower visual recovery (12 to 18 months), substantial induced astigmatism (often 4 to 8 D), highest rejection rate (10 to 30 per cent over the graft's lifetime), and significant biomechanical compromise of the cornea.
• Triple DMEK — DMEK combined with phacoemulsification cataract surgery and IOL implantation in the same operation, the standard pathway for Fuchs dystrophy with co-existent visually significant or near-significant cataract.

The choice depends on whether the disease is isolated to the endothelium (DMEK or DSAEK) or involves the stroma (PK), the anterior segment anatomy, prior surgery and whether there is a co-existent cataract. The decision is always made by a corneal subspecialty consultant.

Who is a good candidate for DMEK?

The strongest case for DMEK applies when one or more of the following are present:

• Fuchs endothelial corneal dystrophy — with symptomatic corneal oedema, morning blur from epithelial bedewing, decreasing BCVA from corneal back-scatter, or progressive guttae confirmed on Pentacam HR posterior elevation and specular microscopy.
• Pseudophakic / aphakic bullous keratopathy — endothelial failure after previous cataract surgery, especially complicated cataract surgery (PCR, anterior chamber IOL).
• Failed previous endothelial graft — failed DMEK, DSAEK or DSEK with persistent endothelial dysfunction confirmed on examination and pachymetry.
• Posterior polymorphous corneal dystrophy (PPCD) with endothelial decompensation.
• Iridocorneal endothelial (ICE) syndrome with progressive endothelial loss and corneal decompensation.
• Congenital hereditary endothelial dystrophy (CHED) in selected cases.
• Failed full-thickness penetrating keratoplasty with endothelial failure but intact donor stroma — DMEK can be performed under a failed PK button.
• Otherwise healthy macula and optic nerve — to ensure the visual benefit of DMEK is not limited by posterior segment disease.

DMEK is not usually appropriate in combined stromal and endothelial disease (e.g. herpetic stromal scar with endothelial failure — PK is preferred), in eyes with a very shallow anterior chamber (technical difficulty in unfolding the graft — DSAEK preferred), in eyes with aniridia or large iris defects (no scaffold for the graft — DSAEK preferred), in heavily vitrectomised eyes (loss of normal anterior chamber dynamics), in eyes with extensive synechiae or glaucoma drainage tubes in the way of graft unfolding, or in eyes with severely compromised macular or optic nerve function where the refractive benefit would be limited. Suitability is always confirmed at a consultant corneal consultation.

NHS vs private DMEK in the UK 2026

NHS access to DMEK in the UK in 2026 is now broad. The procedure is commissioned via the NHS England specialised commissioning corneal transplant pathway and equivalent pathways in NHS Scotland, NHS Wales and NHS Northern Ireland. Donor tissue is supplied by NHS Blood and Transplant (NHSBT) under the UK Transplant Registry, with eye banks in Manchester and Bristol providing pre-cut endothelial grafts to most UK corneal units. Realistic NHS waits run between 6 and 26 weeks from referral to surgery, depending on the trust, the urgency of the case, and donor tissue availability. NHS care is excellent and the only practical limitations are timing and choice of consultant.

Private DMEK in the UK is the practical route when same-month surgery matters (for example, in working-age patients with rapid Fuchs decompensation, or in patients with painful pseudophakic bullous keratopathy); when you want a specific corneal subspecialty consultant with a high DMEK volume; when you have private medical insurance that covers the procedure; or when you want a combined Triple DMEK with premium IOL options not routinely offered on the NHS pathway. Most CQC-registered London corneal centres can complete the consultation, DMEK and 3-month follow-up within an 8 to 12 week window subject to donor tissue availability.

Does private medical insurance cover DMEK?

In 2026 the major UK private medical insurers (Bupa, AXA Health, Aviva, Vitality, WPA) generally cover DMEK when there is a documented diagnosis of an endothelial disease meeting policy criteria: Fuchs endothelial dystrophy with corneal oedema or decreasing BCVA, pseudophakic / aphakic bullous keratopathy, failed previous endothelial graft, posterior polymorphous corneal dystrophy with decompensation, ICE syndrome with corneal decompensation, or congenital hereditary endothelial dystrophy. Coverage typically includes the consultant fee, theatre time, NHSBT donor tissue, anaesthetic, day-case stay and postoperative reviews.

Insurers usually do not cover DMEK for asymptomatic Fuchs guttae without corneal oedema or visual symptoms, for cosmetic or lifestyle indications, or for combined surgery where the cataract component is purely refractive. In a Triple DMEK (DMEK + phaco + IOL), the cataract component is usually covered if a visually significant cataract is documented, but any premium IOL upgrade (toric, EDOF, multifocal) is a self-pay refractive co-payment. The clinical letter must clearly document the diagnosis, the pachymetry, anterior segment OCT findings, endothelial cell count, BCVA, the impact on quality of life, and the rationale for DMEK over DSAEK or conservative management. Always pre-authorise in writing.

Risks and side-effects of DMEK

DMEK is one of the safest corneal transplant techniques but it is intra-ocular surgery and the realistic risks should be set out honestly:

• Graft detachment requiring re-bubbling — the most common DMEK-specific event; in 10 to 25 per cent of eyes in the first 2 weeks. Managed in clinic with a 10-minute air injection. Multiple re-bubbles needed in a small subset.
• Primary graft failure — in 1 to 5 per cent; the graft never clears despite re-bubbling. Managed with repeat DMEK using a new donor.
• Allograft rejection — ~1 to 2 per cent at 1 year and ~3 to 5 per cent over the graft's lifetime, much lower than DSAEK (~5 to 10 per cent) and PK (10 to 30 per cent). Usually responds promptly to topical steroid. Lifelong low-dose topical steroid (e.g. fluorometholone or loteprednol once daily) reduces this further.
• Late endothelial cell density attrition — the graft loses endothelial cells at ~7 to 10 per cent per year for the first few years, slowing thereafter. Late endothelial failure can occur at 10 to 20 years and is treated with repeat DMEK.
• Pupil block from gas bubble — rare, prevented by routine inferior peripheral surgical iridotomy at the 6 o'clock position at the time of surgery; managed by partial bubble release if it occurs.
• Steroid-induced ocular hypertension — 10 to 30 per cent of patients on long-term topical steroid develop a measurable IOP rise; managed with IOP-lowering drops or by switching to a softer steroid (loteprednol, fluorometholone) once the graft is stable.
• Cystoid macular oedema (Irvine-Gass) — in 1 to 5 per cent, particularly in Triple DMEK; managed with topical NSAID and steroid.
• Persistent epithelial defect — uncommon, managed with bandage contact lens and lubricants.
• Postoperative IOP spike — transient, related to gas bubble or steroid; treated with topical or oral IOP-lowering medication.
• Endophthalmitis — very rare, <0.1 per cent, with routine intracameral antibiotic cover; severe but extremely rare.
• Retinal detachment — very rare; small lifetime risk; honest part of consent for any intra-ocular surgery.
• Lifelong graft surveillance — the graft is a transplanted human tissue and the patient should attend annual review with slit-lamp, OCT, specular microscopy and refraction for life.

The overall safety record of DMEK is excellent in experienced UK hands; the technique-specific complications (re-bubbling, primary graft failure) are well-defined and manageable, and the rejection and visual recovery profile are substantially better than DSAEK and PK.

What to expect after DMEK

• Immediately after surgery — supine (flat on back, face up) posturing for 24 to 48 hours to keep the gas / air bubble against the graft. Vision is blurred initially because of the bubble. Mild discomfort, light sensitivity and watering for 24 to 48 hours.
• Day 1 review — slit-lamp examination, anterior segment OCT to confirm graft attachment, IOP check. Topical antibiotic plus intensive topical steroid started.
• Days 1 to 7 — the gas bubble gradually shrinks and is absorbed; vision improves progressively. Avoid swimming, eye rubbing, dusty environments and any strenuous activity that increases IOP. Continue posturing as advised.
• 1-week review — anterior segment OCT to confirm graft attachment, slit-lamp examination, IOP check. Re-bubbling considered if there is greater than one-third graft detachment.
• 1-month review — vision usually 6/12 or better, refraction near-neutral, graft clear, steroid taper started.
• 3-month review — vision usually 6/9 or better in 70 to 85 per cent, refraction stable, graft clear and well-attached, specular microscopy endothelial cell count documented.
• 12-month review — final BCVA, refraction, endothelial cell count and signed-off discharge to annual review. Lifelong low-dose topical steroid usually continued.
• Annual graft surveillance — slit-lamp, anterior segment OCT, specular microscopy, IOP, refraction and consultant review. Patient is encouraged to recognise and report any "RSVP" rejection symptoms (red eye, sensitivity to light, decreased vision, pain) urgently.

How to choose a UK DMEK clinic in 2026

• Clinical leadership — a UK GMC specialist registered consultant ophthalmologist with documented corneal fellowship, doing at least 30 to 50 DMEK procedures a year, with audit data (re-bubbling rate, primary graft failure rate, 1-year endothelial cell density, 1-year BCVA) available on request.
• Full preoperative work-up — slit-lamp, anterior segment OCT, Pentacam HR Scheimpflug tomography, specular microscopy / endothelial cell count, OCT macula — all included in the package, not charged as add-ons.
• NHSBT donor tissue with eye bank pre-cut grafts — the donor cornea should be supplied by NHS Blood and Transplant (NHSBT) under the UK Transplant Registry, with the option of pre-cut pre-stripped DMEK grafts from the Manchester or Bristol eye banks to reduce intra-operative time and risk to the graft.
• Triple DMEK pathway available — combined DMEK plus phacoemulsification plus IOL implantation in the same operation, the standard 2026 pathway for Fuchs dystrophy with co-existent cataract.
• Modern intra-operative imaging — intra-operative OCT (Zeiss Lumera with RESCAN, Leica Proveo, Haag-Streit Hi-R) is increasingly the standard for live confirmation of graft orientation and apposition.
• Honest evidence-based consent — written information about the 10 to 25 per cent early re-bubbling rate, the 1 to 5 per cent primary graft failure rate, the 1 to 2 per cent annual rejection risk, the lifelong endothelial cell density attrition, and the realistic prospect of a repeat DMEK at 10 to 20 years.
• Transparent itemised pricing — the invoice should split consultation, anterior segment imaging, specular microscopy, NHSBT donor tissue, theatre / procedure, re-bubbling and postoperative reviews, so you can claim the appropriate components on insurance and understand what the package actually buys.
• CQC-registered theatre with the latest report rated Good or Outstanding.
• Same consultant throughout — consultation, surgery and all follow-up reviews done by the same corneal subspecialty consultant.
• Annual graft surveillance on offer — the clinic should offer a structured annual graft surveillance package and lifelong follow-up.
• Direct access — a published 24/7 number for postoperative concerns and a same-day clinic slot if any rejection symptoms (red eye, sensitivity to light, decreased vision, pain) develop.

Frequently asked questions

How much does private DMEK corneal transplant cost in the UK in 2026?

UK 2026 self-pay DMEK costs 6,500 to 10,500 pounds per eye, all-inclusive at CQC-registered UK corneal centres. The fee covers the consultant corneal assessment, anterior segment OCT, Pentacam HR Scheimpflug tomography, specular microscopy endothelial cell count, the NHS Blood and Transplant (NHSBT) donor tissue fee (a substantial pass-through line-item, typically 900 to 1,400 pounds per graft), the day-case DMEK procedure under topical or sub-Tenon's anaesthetic with intra-operative air or 20 per cent SF6 gas tamponade, and the structured 1-day, 1-week, 1-month, 3-month and 12-month reviews. Re-bubbling within 2 weeks is included. A combined Triple DMEK (DMEK plus phacoemulsification plus IOL) is typically 8,500 to 13,500 pounds per eye.

Why is DMEK better than DSAEK or full-thickness corneal transplant?

DMEK replaces only the diseased ~15 micron Descemet membrane and endothelium, so the patient's own anterior cornea is preserved. This gives a faster visual recovery (6/9 or better in 70 to 85 per cent at 3 to 6 months, versus 6/12 by 3 to 6 months with DSAEK and 12 to 18 months for stable vision with PK), a near-neutral refraction (~+0.25 D hyperopic shift versus ~+1.25 D for DSAEK and 4 to 8 D astigmatism for PK), a substantially lower rejection rate (1 to 2 per cent at 1 year versus 5 to 10 per cent for DSAEK and 10 to 30 per cent for PK), and much better preserved corneal biomechanics. The trade-off is a higher early re-bubbling rate (10 to 25 per cent for DMEK versus 3 to 5 per cent for DSAEK), which is managed in clinic.

How long does DMEK take and is it painful?

DMEK takes 30 to 60 minutes per eye under topical or sub-Tenon's anaesthetic as a day-case. You are awake but the eye and the eye socket are numb. There is no real pain during surgery, just a sense of pressure. Postoperatively there is mild discomfort, light sensitivity and watering for 24 to 48 hours. Vision is initially blurred because of the gas / air bubble in the anterior chamber, which gradually shrinks and is absorbed over the first week.

How long does the visual recovery from DMEK take?

Vision improves progressively as the gas bubble is absorbed and the donor endothelium pumps fluid out of the cornea. Most patients reach 6/12 by 4 to 8 weeks and 6/9 or better in approximately 70 to 85 per cent of eyes by 3 to 6 months. The refraction is essentially neutral (small hyperopic shift of ~+0.25 D), so glasses are usually not significantly changed unless a Triple DMEK has been done with a new IOL.

What is re-bubbling and how often is it needed?

Re-bubbling is a 10-minute in-clinic procedure to inject air into the anterior chamber if the DMEK graft detaches more than one-third within the first 2 weeks (detected on anterior segment OCT). It is needed in 10 to 25 per cent of DMEKs and is a routine part of DMEK care, not a complication of the surgery. It is performed under topical anaesthetic and is essentially painless. Most UK private DMEK packages include re-bubbling at no additional charge.

Will the NHS pay for my DMEK?

Yes. DMEK is commissioned via the NHS England specialised commissioning corneal transplant pathway and equivalent pathways in Scotland, Wales and Northern Ireland. Donor tissue is supplied by NHS Blood and Transplant (NHSBT) with eye banks in Manchester and Bristol providing pre-cut endothelial grafts. Realistic NHS waits run between 6 and 26 weeks from referral to surgery depending on the trust and donor tissue availability. NHS care is excellent and the only practical limitations are timing and choice of consultant.

Will my private medical insurance cover DMEK?

In 2026 Bupa, AXA Health, Aviva, Vitality and WPA generally cover DMEK when there is a documented diagnosis of an endothelial disease meeting policy criteria: Fuchs endothelial dystrophy with corneal oedema or decreasing BCVA, pseudophakic or aphakic bullous keratopathy, failed previous endothelial graft, posterior polymorphous corneal dystrophy with decompensation, ICE syndrome with corneal decompensation, or congenital hereditary endothelial dystrophy. The clinical letter must document the diagnosis, the pachymetry, anterior segment OCT findings, endothelial cell count, BCVA, the impact on quality of life and the rationale for DMEK. Always pre-authorise in writing.

How long does a DMEK graft last?

The DMEK graft loses endothelial cells at approximately 7 to 10 per cent per year for the first few years and the rate slows thereafter. Most DMEK grafts function well for 10 to 20 years or more in clean uncomplicated Fuchs eyes. If the graft eventually fails because of endothelial cell exhaustion or rejection, a repeat DMEK can be performed. The 1 to 2 per cent annual rejection rate is much lower than DSAEK (~5 to 10 per cent over the graft's life) or PK (10 to 30 per cent).

Do I have to take steroid eye drops for life after DMEK?

Most UK corneal surgeons continue a low-dose topical steroid (e.g. fluorometholone or loteprednol once daily) for life after DMEK, because it substantially reduces the long-term rejection rate. The dose is titrated against IOP, which can rise with chronic steroid use in around 10 to 30 per cent of patients (steroid response); in those patients a softer steroid is used or an IOP-lowering drop is added. Lifelong adherence and annual graft surveillance are essential.

What are the symptoms of graft rejection and what should I do?

The classic rejection symptoms are summarised as "RSVP": Redness, Sensitivity to light (photophobia), Vision loss (sudden blur or fog), and Pain. If any of these develop, contact the corneal team urgently and be seen the same day if possible. Rejection is treated with intensified topical steroid (sometimes oral steroid) and usually responds promptly if caught early. Lifelong low-dose topical steroid maintenance significantly reduces the risk.

When can I drive after DMEK?

Most patients drive within 1 to 4 weeks of DMEK, depending on the speed of visual recovery in the operated eye and the vision in the fellow eye. The DVLA requirement is binocular Snellen 6/12 vision with both eyes open and a horizontal field of vision of at least 120 degrees. Your consultant will sign off driving at the 2-week or 4-week review once the gas bubble has absorbed and vision has recovered.

Can I have DMEK if I have already had cataract surgery, glaucoma surgery or PK?

Yes, in many cases. Pseudophakic bullous keratopathy after previous cataract surgery is one of the strongest DMEK indications. Eyes with previous glaucoma drainage devices, trabeculectomy or tube shunts can have DMEK but the technical difficulty is higher and DSAEK may be preferred if the anterior chamber dynamics are altered. DMEK can also be performed under a previously failed full-thickness PK button to restore endothelial function. The decision is always made by a corneal subspecialty consultant after full anterior segment imaging.

DMEK versus DSAEK versus PK — which is right for me?

DMEK is the modern gold standard for isolated endothelial disease where technically feasible (fastest recovery, best BCVA, lowest rejection). DSAEK is reserved for eyes where DMEK is technically unsafe (very shallow anterior chamber, aniridia, large iris defects, vitrectomised eyes, glaucoma drainage devices). Penetrating keratoplasty (PK) is reserved for combined stromal and endothelial disease (e.g. herpetic scar with endothelial failure). See our DSAEK guide and our DMEK vs DSAEK vs PK overview.

Methodology and sources

This UK 2026 patient pricing and pathway guide was prepared by the Eye Surgery Clinic editorial team and reviewed by a UK GMC-registered consultant ophthalmologist with corneal subspecialty interest. Pricing reflects a CQC-registered UK corneal sample audited against published 2024 to 2026 self-pay tariffs from the major UK corneal transplant providers. Clinical statements are anchored on:

• Melles GRJ, et al. Descemet membrane endothelial keratoplasty (DMEK). Cornea 2006; 25(8): 987-990
• Melles GRJ, et al. A technique to excise the Descemet membrane from a recipient cornea (DMEK). Br J Ophthalmol 2008
• Price MO, Price FW, et al. Descemet membrane endothelial keratoplasty - prospective multicentre data. Ophthalmology 2014, 2016, 2018
• NICE IPG 632 Descemet membrane endothelial keratoplasty (DMEK) (2019)
• NHS Blood and Transplant (NHSBT) UK Transplant Registry / Ocular Tissue Advisory Group (OTAG)
• Royal College of Ophthalmologists Corneal Transplantation Commissioning Guidance
• European Eye Bank Association (EEBA) and Eye Bank Association of America (EBAA) donor tissue standards
• EuCornea / ESCRS Cornea Day Working Group statements on DMEK and endothelial keratoplasty
• American Academy of Ophthalmology Cornea Preferred Practice Pattern
• Cochrane Database of Systematic Reviews on endothelial keratoplasty
• Care Quality Commission (CQC) inspection reports for major UK corneal units
• General Medical Council (GMC) Good Medical Practice and consent guidance

This page is editorial and educational. It is not personalised medical advice. DMEK suitability can only be confirmed by an in-person corneal subspecialty consultation with a full anterior segment work-up.

Book your UK DMEK consultation

Speak directly to a UK GMC-registered consultant ophthalmologist with corneal subspecialty interest. Same-week consultation slots are usually available. Slit-lamp, anterior segment OCT, Pentacam HR Scheimpflug tomography, specular microscopy endothelial cell count and OCT macula included. Confidential, no-obligation review of whether DMEK, DSAEK or PK is right for you.

Related reading: Private corneal transplant cost UK · Private DSAEK corneal transplant London · Corneal transplant options overview · Fuchs endothelial dystrophy treatment UK